Allogene Therapeutics

Yahoo Finance • 3 months ago

Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now

We recently compiled a list of the 7 Best Rising Penny Stocks To Invest In Now.In this article, we are going to take a look at where Allogene Therapeutics, Inc. (NASDAQ:ALLO) stands against the other rising penny stocks. Fed’s Rate Cut Se... Full story

Yahoo Finance • last year

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call Transcript

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call Transcript November 2, 2023 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.37, expectations were $-0.53. Operator: Hello, and thank you for sta... Full story

Yahoo Finance • last year

Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting

Cloak™ and Dagger™ Technologies Show Potential to Reduce Dependence on Standard Lymphodepletion and Enhance Performance of AlloCAR T™ CellsData from Preclinical Study of Cloak™ Technology Highlights Ability to Engineer Allogeneic Cells to... Full story

Yahoo Finance • last year

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting

Research Provides Early Validation of ALLO-182, an AlloCAR T™ Candidate in the IND-Enabling Phase of Development Targeting Claudin18.2 for the Treatment of Patients with Gastric and Pancreatic Cancers SOUTH SAN FRANCISCO, Calif., Nov. 03... Full story

Yahoo Finance • last year

Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

Preclinical Posters to Be Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on the Next Generation AlloCAR T™ Platform Cloak ™ and Dagger™ Technologies Highlighted Potential to Enhance Engraftment, Expansion and P... Full story

Yahoo Finance • last year

Allogene Therapeutics Announces Participation in November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today anno... Full story

Yahoo Finance • last year

Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today anno... Full story

Yahoo Finance • last year

Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appoin... Full story

Yahoo Finance • last year

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Spotlight on Novel, Targeted Technologies to Enhance Engraftment, Expansion and Persistence of AlloCAR T™ Cells Demonstration of Dagger™ Technology to Engineer CAR T cells to Selectively Eliminate CD70 Positive, Allo-Reactive Host Immune... Full story

Yahoo Finance • last year

Allogene Therapeutics Announces Participation in September Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today ann... Full story

Yahoo Finance • last year

11 Best High Short Interest Stocks To Buy Now

In this piece, we will take a look at the 11 best high short interest stocks to buy now. If you want to skip our introduction to short selling and short interest, then take a look at 5 Best High Short Interest Stocks To Buy Now. Short sel... Full story

Yahoo Finance • 2 years ago

Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

Presentation Includes Data on All 33 CAR T-Naïve Patients Treated with the Alloy™ Manufactured Material and Recaps Data on 12 Large B Cell Lymphoma Patients Treated with Phase 2 Dose RegimenResults Indicate an Off-the-Shelf Allogeneic CAR... Full story

Yahoo Finance • 2 years ago

Allogene Therapeutics Announces Departure of Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, announced... Full story

Yahoo Finance • 2 years ago

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano

Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous TherapiesPresentation Recaps 12 Patients Treated with Phase 2 D... Full story

Yahoo Finance • 2 years ago

12 Best Short Squeeze Stocks to Buy Now

In this article we present the list of 12 Best Short Squeeze Stocks to Buy Now. Click to skip ahead and see the 5 Best Short Squeeze Stocks to Buy Now. Plug Power, Inc. (NASDAQ:PLUG), Cinemark Holdings, Inc. (NYSE:CNK), and Allogene Thera... Full story

Yahoo Finance • 2 years ago

Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company’s genomic medicine and engineered NK cell therapy pipelineFormer Chief Medi... Full story

Yahoo Finance • 2 years ago

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

Enrollment Ongoing in Industry’s First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed/Refractory Large B Cell LymphomaInitiated Phase 2 EXPAND Trial to Support Licensure of ALLO-647 as a Lymphodepleting Agent for A... Full story

Yahoo Finance • 2 years ago

Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today ann... Full story

Yahoo Finance • 2 years ago

Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

Former Kite Pharma Executive Responsible for the Development and Commercial Launch of Two of the Most Successful Autologous CAR T Manufacturing Processes in the Industry Brings Unique Experience as a CAR T Pioneer in Advancing Next Generat... Full story

Yahoo Finance • 2 years ago

Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting

Data Provide Proof-of-Concept for an Allogeneic Anti-CD70 CAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting Therapy Single Infusion of ALLO-316 Demonstrates Promis... Full story